A Phase 1/2 interventional study of AC-101 in Ulcerative Colitis, sponsored by Accro Bioscience (Suzhou) Limited. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Accro Bioscience (Suzhou) Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Colitis, Ulcerative with a site in China — 73 open to participants now, 96 under way, 25 of them phase 3. Colitis, Ulcerative · China.
Among the 184 studies in Colitis, Ulcerative with a site in China, this one is the 124th largest by enrollment of the 136 interventional ones that give a count, is one of 30 that started in 2025, is one of 7 in phase 1/2, and was the 130th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →73 of the 184 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:
Accro Bioscience (Suzhou) Limited · Sites in China
Ages 18–75
Nanjing Immunophage Biotech Co., Ltd · Sites in China
Ages 18–70
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
Innatus Therapeutics (Shanghai) Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 47 · Phase 3 37 · Phase 4 11
First in 2009; this study’s year is marked. 30 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 121 across the 136 interventional studies, 176 across the 48 observational. Of the 58 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 184 have an industry lead sponsor. The 10 most frequent:
Accro Bioscience (Suzhou) Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Accro Bioscience (Suzhou) Limited has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
27 of the studies in Colitis, Ulcerative with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
Add all 27 to your calendar (.ics) → With an account.
Among the 184 studies in Colitis, Ulcerative with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis.
The total study duration is up to 17 weeks, including 4-week screening, 12-week treatment period, and 1-week safety follow-up.
The study will enroll approximately 24 participants with moderate to severe active ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of active UC defined by modified Mayo score of 5 to 9 points (inclusive) with 3 subscores meeting the followings:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive AC-101 Dose 1 as tablets orally twice daily from Week 0 through W12
Drug: AC-101
Participants will receive AC-101 Dose 2 as tablets orally once daily from Week 0 through W12
Drug: AC-101
AC-101 tablets will be administered orally.
Incidence and Severity of Adverse Events
An Adverse Event (AE) is defined as any new untoward medical condition or worsening of a pre-existing medical condition following or during exposure to an investigation product, whether or not considered causally related to the product.
Time frame: Up to Week 13
Proportion of Participants Achieved Clinical Response
Clinical response is defined as achieving the following changes in the modified Mayo score (excludes the physicians' global assessment) 1. A decrease from baseline in modified Mayo score of ≥ 2 points, and 2. A decrease from baseline in modified Mayo score of ≥ 30%, and 3. A decrease from baseline in rectal bleeding (RB) subscore of ≥ 1 point or absolute RB subscore ≤ 1 point The modified Mayo score is a sum of the following 3 subscores: 1. Stool frequency (SF) subscore (0-3) 2. Rectal bleeding (RB) subscore (0-3) 3. Endoscopic (ES) subscore (0-3)
Time frame: Week 12
Proportion of Participants achieved Clinical Remission
Clinical remission is defined as achieving the following changes in the modified Mayo score 1. Absolute modified Mayo score ≤ 2 points, and 2. Absolute SF subscore ≤ 1 point, and 3. Absolute RB subscore = 0 point, and 4. Absolute ES subscore ≤ 1 point
Time frame: Week 12
Ran from Jan 2025 to primary completion in Apr 2026, 15 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Sep 2026 → Apr 2026 and completion Apr 2027 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Accro Bioscience (Suzhou) Limited